Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers
  • 5.0 (5)
  • Medicine

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

  1. ASCO 2026 GU Highlights & FDA Approvals with Drs. Brian Rini & Tom Powles (The Uromigos)

    2d ago ·  Video

    ASCO 2026 GU Highlights & FDA Approvals with Drs. Brian Rini & Tom Powles (The Uromigos)

    Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast.   In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space: PROTEUS:  trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm. TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance. CAPITELLO-281: insights into the recent approval of this AKT inhibitor for metastatic castration-sensitive prostate cancer with PTEN loss, based on the CAPItello-281 study. EV-302 update: combination of EV-pembrolizumab still maintains the doubling of survival benefit with longterm follow up. POTOMAC: durvalumab + BCG induction therapy for high-risk non-muscle invasive bladder cancer (NMIBC) could be a choice for a selected patient population. LITESPARK-022: The new approval of belzutifan with pembrolizumab in the adjuvant setting, discussing its efficacy and the importance of patient selection.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o ' Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Throughout the episode, we emphasized the importance of balancing treatment benefits with potential adverse events, as well as the need for shared decision-making in clinical practice. #GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer, #RenalCellCarcinoma, #OncologyBrothers

    34 min
  2. To hold or NOT to hold Systemic Therapy with Radiation: Dr. Nina Sanford

    6d ago ·  Video

    To hold or NOT to hold Systemic Therapy with Radiation: Dr. Nina Sanford

    Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Nina Sanford, a GI radiation oncologist from UT Southwestern, to discuss a critical topic in cancer treatment: when to hold and not to hold systemic therapy during radiation and for how long.   Join us as we explore: The framework for balancing systemic therapy with different types of radiation, including SBRT, palliative, and conventional radiation. Insights on managing cytotoxic chemotherapy, immunotherapy, TKIs, and targeted therapies in conjunction with radiation. The importance of individualized treatment plans and the evolving data around various drug classes, including BRAF inhibitors, PARP inhibitors, and anti-HER2 therapies. Practical recommendations for community oncologists navigating these complex decisions.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to check out Dr. Sanford's teaching video for more in-depth information! #RadiationOncology, #SystemicTherapy, #SBRT, #MultidisciplinaryCare, #OncologyBrothers

    24 min
  3. ASCO 2026 GI Highlights: EMERALD-3, FIGHT-302, CIRCULATE, MATTERHORN

    Jun 15 ·  Video

    ASCO 2026 GI Highlights: EMERALD-3, FIGHT-302, CIRCULATE, MATTERHORN

    Welcome back to the Oncology Brothers podcast! In this episode we are joined by Dr. Neena Vijayvergia from Fox Chase Cancer Center to discuss the latest highlights from ASCO 2026, focusing on gastrointestinal (GI) studies.   We discussed key studies: EMERALD-3 in HCC: Exploring the findings on combining TACE with Durvalumab and Tremelimumab, and the implications for patient outcomes. FIGHT-302 in Cholangiocarcinoma: The potential of FGFR inhibitors in frontline settings and the challenges of biomarker testing. CIRCULATE Update: The role of ctDNA in stage 2 colon cancer and how it influences treatment decisions. MATTERHORN Update: Benefits of perioperative chemotherapy and the importance of maintaining treatment regimens for better patient outcomes. We also touched on the evolving landscape of GI malignancies and the significance of multidisciplinary approaches in treatment planning. Tune in for an informative discussion that aims to enhance your understanding of the latest advancements in oncology and their practical applications in the clinic.    Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Don't forget to subscribe for more updates on treatment algorithms, challenging cases, and conference highlights! #ASCO2026, #GIOncology, #ctDNA, #FGFRinhibitor, #OncologyBrothers

    24 min
  4. RASolute 302 Pancreatic Cancer Study with Daraxonrasib at ASCO 2026 – Dr. Brian Wolpin

    Jun 11 ·  Video

    RASolute 302 Pancreatic Cancer Study with Daraxonrasib at ASCO 2026 – Dr. Brian Wolpin

    In this episode of the Oncology Brothers podcast, we dived deep into the groundbreaking RASolute 302 study on pancreatic cancer, featuring special guest Dr. Brian Wolpin, a leading oncologist from Dana-Farber Cancer Institute.   We discussed: The significance of RAS mutations in pancreatic cancer, which affect over 90% of patients. The trial design and key findings of the RASolute 302 study, highlighting the impressive doubling of overall survival from 6.6 months to 13.2 months with the new drug, Daraxonrasib. The mechanism of action of Daraxonrasib as a RAS-on inhibitor and its unique properties compared to other RAS inhibitors. Common side effects associated with the drug, including rash, diarrhea, and stomatitis, and strategies for managing these in clinical practice. The importance of biomarker testing and the implications for treatment in all pancreatic cancer patients.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Tune in to learn how this new therapy could change the landscape of treatment for pancreatic cancer patients. Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in cancer research and treatment! #PancreaticCancer, #Daraxonrasib, #ASCO2026, #RASmutation, #OncologyBrothers

    23 min
  5. ASCO 2026 Head & Neck AND Sarcoma Highlights – Drs. Samantha Armstrong & Ari Rosenberg

    Jun 8 ·  Video

    ASCO 2026 Head & Neck AND Sarcoma Highlights – Drs. Samantha Armstrong & Ari Rosenberg

    Welcome back to the Oncology Brothers podcast! In this episode, we dived into the key highlights from ASCO 2026, focusing on groundbreaking studies in head and neck cancer and sarcoma. Join us as we discuss: Nasopharyngeal Carcinoma: comparing carboplatin and cisplatin in induction and concurrent chemoradiation therapy. Can we extrapolate these findings to other head and neck cancers? Amivantamab in Head and Neck Cancer: Insights from the OrigAMI4 study, showcasing the efficacy of amivantamab in refractory settings, with an impressive overall response rate of 47%. SARC041: A look at abemaciclib as a treatment for de-differentiated liposarcoma, highlighting significant improvements in progression-free survival. Gastrointestinal Stromal Tumors (GIST): The PEAK trial results, explored the combination of bezuclastinib and sunitinib after progression on imatinib, showing promising outcomes.   We are thrilled to have Dr. Ari Rosenberg from the University of Chicago and Dr. Sam Armstrong from Indiana University join us to share their expertise and insights on these important studies.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o   Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/   Tune in for an informative discussion that sheds light on the latest advancements in oncology! Don’t forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers.   #ASCO2026, #HeadAndNeckCancer, #Sarcoma, #GIST, #OncologyBrothers

    25 min
  6. Challenging Cases - Treatment of Common EGFR Mutations in Metastatic Non-Small Cell Lung Cancer

    Jun 8 ·  Video

    Challenging Cases - Treatment of Common EGFR Mutations in Metastatic Non-Small Cell Lung Cancer

    In this episode of the Oncology Brothers podcast, we discussed challenging cases focused on metastatic non-small cell lung cancer (NSCLC) with common EGFR mutations. Joined by experts Dr. Shirish Gadgeel from the Emory University and Dr. Wade Iams from Tennessee Oncology, the discussion revolved around two real-life patient cases. The first case featured a 54-year-old gentleman with active tobacco use and diffusely metastatic NSCLC, including an isolated brain lesion. The panel explored treatment options, including single-agent osimertinib versus dual combinations of amivantamab-lazertinib and osimertinib-chemotherapy, emphasizing the importance of shared decision-making and considering co-mutations and patient demographics. In the second case, the conversation shifted to supportive care and managing side effects, particularly focusing on skin toxicity associated with amivantamab. The experts shared their proactive approaches to patient education and the significance of monitoring and adjusting treatment plans to enhance patient quality of life.   Key Points: In EGFR-mutated NSCLC with CNS metastases, treatment selection between single-agent osimertinib and combination amivantamab-lazertinib vs. osimertinib-chemotherapy requires individualized consideration of age, co-mutations, extent of disease, and patient preference rather than mutation status alone. Younger patients with CNS disease may benefit from more aggressive upfront combination therapy, while shared decision-making remains central to navigating the expanded efficacy versus increased toxicity trade-off. Dermatologic toxicities associated with amivantamab requires proactive management including supportive care regimen, early dose adjustments and close patient monitoring to maintain treatment continuity. Providing the best available upfront therapy in metastatic EGFR-mutated NSCLC is critical, as sequencing options become more limited at progression. Join us for an insightful discussion on the latest treatment algorithms, the importance of personalized care, and the evolving landscape of NSCLC management.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Don't forget to subscribe for more episodes featuring conference highlights and challenging cases in oncology! #EGFRMutated, #LungCancer, #ThoracicOncology, #PersonalizedMedicine, #OncologyBrothers

    24 min
  7. Lung Cancer ASCO 2026 Highlights: LIBRETTO-432, CROWN Update, CHRYSALIS-2, HARMONi-6

    Jun 5 ·  Video

    Lung Cancer ASCO 2026 Highlights: LIBRETTO-432, CROWN Update, CHRYSALIS-2, HARMONi-6

    Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Isabel Preeshagul from Memorial Sloan-Kettering to discuss the latest advancements in lung cancer presented at ASCO 2026. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We dived into four key studies that could change clinical practice: LIBRETTO-432: exploring the promising event-free survival data with selpercatinib in RET-positive disease and its implications for adjuvant therapy. CROWN 7yr Update: seven-year progression-free survival results with lorlatinib in ALK-positive non-small cell lung cancer and the associated side effects. CHRYSALIS-2: exciting findings regarding amivantamab for atypical EGFR mutations and its potential to become the new standard of care. HARMONi-6: dual-headed drug ivonescimab combined with chemotherapy in metastatic squamous cell lung cancer and its intriguing results. We also touched on the importance of molecular testing for all patients, regardless of stage or histology, and highlighted the latest updates on tarlatamab in small cell lung cancer. Tune in for an insightful discussion that aims to keep our oncology community informed and engaged with the latest research and treatment options! Don't forget to like, subscribe, and check out our other episodes for more insights on oncology treatments, conference highlights, and FDA approvals. #ASCO2026, #LungCancer, #ALKPositive, #RETPositive, #OncologyBrothers

    22 min
  8. RASolute-302 with Daraxonrasib - Game Changer at ASCO 2026 in Pancreatic Cancer

    Jun 1 ·  Video

    RASolute-302 with Daraxonrasib - Game Changer at ASCO 2026 in Pancreatic Cancer

    Join us as we bring you the latest insights from ASCO 2026! In this episode, we dived deep into the groundbreaking RASolute-302 study, which has made waves in the treatment of metastatic pancreatic cancer. Discover how the novel RAS inhibitor, Daraxonrasib, has doubled overall survival rates from 6.7 months to an impressive 13.2 months for patients in the second-line setting. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We were joined by esteemed experts Dr. Rachna Shroff, Dr. Shubham Pant, Dr. Eileen O'Reilly, and Dr. Andrew Ko, who shared their insights on the study's design, findings, and the implications for our clinical practice. We touched on the prevalence of RAS mutations in pancreatic cancer, the mechanism of action of Daraxonrasib, and the side effect profile that clinicians need to manage effectively. Topics Covered: Overview of the RASolute-302 study Impact of Daraxonrasib on overall survival RAS mutations in pancreatic cancer Mechanism of action of RAS inhibitors Side effects and management strategies Tune in now for an enlightening discussion on the future of pancreatic cancer treatment! #ASCO2026, #PancreaticCancer, #Daraxonrasib, #RASmutation, #OverallSurvival

    27 min
See All (100)

5
out of 5
5 Ratings

About

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

Information

You Might Also Like